2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

2:30PM-4:00PM: Abstract Number: 2002

Dnase Treatment Protects Against DVT Formation in a Mouse Model of Antiphospholipid Syndrome

Antiphospholipid Syndrome: Recent findings

2:30PM-4:00PM: Abstract Number: 2077

Does Dysbiosis within the Intestinal Microbiome Contribute to SLE Pathogenesis?

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Modulators of Disease

2:30PM-4:00PM: Abstract Number: 2074

Dominant Chilblain Lupus Due to an Activating Mutation of Sting – Suppression of Constitutive Type I Interferon Activation By JAK Inhibition

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Modulators of Disease

2:30PM-4:00PM: Abstract Number: 2039

Effect of Adalimumab on Visual Functioning (VFQ-25) in Visual-1 Trial Patients with Non-Anterior Non-Infectious Uveitis

Miscellaneous Rheumatic and Inflammatory Diseases Oral Session II

2:30PM-4:00PM: Abstract Number: 2006

Effect Size of the Anti-Aggrecanase-2 Monoclonal Antibody CRB0017 in Rodent Models of Osteoarthritis

Biology and Pathology of Bone and Joint: Ostearthritis Pathogenesis

2:30PM-4:00PM: Abstract Number: 2079

Effectiveness of Renoprotective Approaches in Lupus Nephritis: More Than Just Immunosuppression

ARHP II: Lupus

2:30PM-4:00PM: Abstract Number: 2058

Efficacy and Safety of Rituximab Biosimilar Candidate (CT-P10) and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase I Randomized Controlled Trial over 72 Weeks

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy III: Biosimilars

2:30PM-4:00PM: Abstract Number: 2020

Elevated BMI and ACPA Together Increase RA Risk and Independently Accelerate Time to RA

Epidemiology and Public Health II: RA and Lifestyle Factors

2:30PM-4:00PM: Abstract Number: 2066

Elevated Innate, Adaptive, and TNF-Superfamily Soluble Inflammatory Mediators Mark Impending Disease Flare, While Regulatory Mediators Distinguish Lack of Impending Disease Flare in African-American SLE Patients with Active Disease

Systemic Lupus Erythematosus - Clinical Aspects and Treatment III: Biomarkers

2:30PM-4:00PM: Abstract Number: 2082

Evaluations of Social Support Are Associated with Well-Being Outcomes in Women with Systemic Lupus Erythematosus (SLE)

ARHP II: Lupus

2:30PM-4:00PM: Abstract Number: 2029

Fever of Unknown Origin (FUO) and Inflammation of Unknown Origin (IUO): Is 18f-FDG-PET/CT a Useful First Line Diagnostic Strategy?

Imaging of Rheumatic Diseases II: MRI, PET and CT

2:30PM-4:00PM: Abstract Number: 2016

Functional Tertiary Lymphoid Structures within the Kidneys of Lupus Prone Mice Resembles Lymph Nodes in Gene Expression Profiling Analysis and Are Detected By in Vivo Imaging

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

2:30PM-4:00PM: Abstract Number: 2050

Herpes Zoster during the Tofacitinib Clinical Development Program for RA: Characterization of Herpes Zoster Incidence and Evaluation of Whether Herpes Zoster Predicts Subsequent Serious Infections or Malignancy

Rheumatoid Arthritis - Clinical Aspects II: Infection, Malignancy and Other Comorbidites in RA

2:30PM-4:00PM: Abstract Number: 2069

High Interferon Gene Signature Is Associated with Increased Disease Activity, Reduced Complement C3 and C4, and Increased Oral Corticosteroid Use in Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus - Clinical Aspects and Treatment III: Biomarkers

2:30PM-4:00PM: Abstract Number: 2048

Hospitalization Trends of Rheumatoid Arthritis and Gout in the United States: A Crossroad

Rheumatoid Arthritis - Clinical Aspects II: Infection, Malignancy and Other Comorbidites in RA

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].